Ozempic’s top dose lost 20.9 pounds. Retatrutide’s top dose lost 47.4. Eli Lilly’s experimental drug just beat Novo Nordisk’s Ozempic head to head, and that gap is why your phone is lighting up.
In a Phase 3 trial of adults with type 2 diabetes, the drug lost more than double the weight of Ozempic’s top dose. That is the retatrutide vs Ozempic story in one line, and Lilly announced it today.
The numbers behind the retatrutide vs Ozempic headline
Here is what Lilly reported after 80 weeks. Patients on retatrutide 9 mg lost an average of 44.3 pounds, or 19.5% of body weight. Those on the 12 mg dose lost 47.4 pounds, or 20.9%. Ozempic at 2 mg, its highest approved dose for diabetes, lost 20.9 pounds, or 9.4%. If you want the full breakdown, see our earlier report on how retatrutide broke the diabetes weight-loss rule.
Blood sugar tells a similar story. Both retatrutide doses cut A1C by an average of 2.2%, against 1.8% for Ozempic. A1C is the standard measure of average blood sugar over about three months. Reuters adds that retatrutide also beat Ozempic on certain cardiovascular risk factors.
That A1C number is likely why people are searching for this study by name. It is the headline metric, and it is a real gap.
Why a triple-hormone drug changes retatrutide compared with Ozempic
Ozempic copies one gut hormone, GLP-1. Lilly’s Mounjaro adds a second one, GIP. Retatrutide, a once-weekly shot, goes after three: GLP-1, GIP and glucagon, a hormone tied to burning fat. That is where the “triple-G” nickname comes from, as ABC News explains. It also explains why retatrutide versus Ozempic is not an even fight on paper (one hormone against three is a lot like bringing a bigger toolbox).
Lilly calls this the first Phase 3 trial to pit retatrutide against another incretin drug. Kenneth Custer, who runs Lilly’s cardiometabolic business, says that if regulators approve it, retatrutide “could shift the treatment paradigm” for diabetes, obesity and related conditions.
Here’s the thing: read the Lilly retatrutide Ozempic trial’s fine print
Big numbers deserve a close read. Here is what to keep in mind before anyone declares a winner.
First, this is a press release, not a peer-reviewed paper. Lilly has not published the full data yet. That gap matters for judging any retatrutide vs Ozempic claim.
Second, Lilly’s figures rely on what is called an efficacy estimand. In plain English, that assumes people stayed on the drug. In the real world, plenty of people stop, and results usually look smaller.
Third, this was a comparison with Ozempic, not Wegovy and not Lilly’s own Mounjaro. Lilly’s head-to-head against tirzepatide, called TRIUMPH-5, is still running. That one will tell us whether retatrutide beats the newer generation, not just the first.
Fourth, nothing so far says retatrutide is gentler. Earlier Lilly trials showed more people quitting for side effects as the dose went up. In the big TRIUMPH-1 study, dropouts ran 4.1%, 6.9% and 11.3% across the three doses. Nausea hit 26.5% of patients on the top dose in an earlier diabetes trial. A small share also reported an odd skin sensation called dysesthesia, mostly mild. We do not yet have the side-effect table for this specific trial. Our look at what the evidence really shows on weight-loss drugs offers useful context on benefits and risks.
What it means for your wallet
Nothing changes today. Retatrutide is investigational, and the law bars anyone from selling it. ABC reports Lilly plans to file with the FDA in early 2027, so any approval is further out than that.
Lilly has not announced price or insurance coverage, so ignore anyone telling you what it will cost. And if you see retatrutide for sale online, the FDA says that is black-market product and you should not consume it.
If you are on Ozempic or weighing a GLP-1 drug, this is a conversation for your doctor, not a reason to switch anything on your own.
Wall Street noticed. Lilly shares were around $1,281.91 when the news hit, per GuruFocus. I could not find a response from Novo Nordisk yet.
So who wins this one? On paper, Lilly. In your medicine cabinet, nobody wins until the full data lands and the FDA weighs in. The question worth watching is TRIUMPH-5, because beating Ozempic is one thing and beating Lilly’s own Mounjaro is the real prize.
